Ani Pharmaceuticals Stock Shares Owned By Insiders

ANIP Stock

USD 55.86 0.76 1.38%

ANI Pharmaceuticals fundamentals help investors to digest information that contributes to ANI Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of ANI Stock. The fundamental analysis module provides a way to measure ANI Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ANI Pharmaceuticals stock.

Other Current Liab Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

ANI Pharmaceuticals Company Shares Owned By Insiders Analysis

ANI Pharmaceuticals' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current ANI Pharmaceuticals Shares Owned By Insiders

11.10 %

Most of ANI Pharmaceuticals' fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ANI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

ANI Shares Owned By Insiders Driver Correlations

Understanding the fundamental principles of building solid financial models for ANI Pharmaceuticals is extremely important. It helps to project a fair market value of ANI Stock properly, considering its historical fundamentals such as Shares Owned By Insiders. Since ANI Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ANI Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ANI Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Current Deferred Revenue	Net Receivables	Net Tangible Assets	Long Term Debt	Good Will	Long Term Debt Total	Long Term Investments	Treasury Stock	Intangible Assets	Property Plant Equipment	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock	Accumulated Depreciation
Total Assets		1.0	0.59	0.16	0.94	0.99	0.95	-0.48	-0.18	0.61	0.97	0.09	0.87	0.9	0.67	0.65	-0.81	0.81	0.92	0.88	-0.8	0.83	0.8	0.81	-0.73
Total Stockholder Equity	1.0		0.52	0.15	0.94	0.98	0.96	-0.48	-0.14	0.64	0.95	0.15	0.86	0.91	0.66	0.68	-0.77	0.77	0.9	0.88	-0.76	0.84	0.82	0.81	-0.73
Net Debt	0.59	0.52		0.34	0.44	0.66	0.3	-0.44	-0.21	0.06	0.65	-0.5	0.68	0.39	0.57	-0.06	-0.78	0.9	0.72	0.61	-0.68	0.38	0.16	0.45	-0.29
Retained Earnings	0.16	0.15	0.34		-0.06	0.18	0.04	-0.89	0.4	0.08	0.09	-0.18	0.24	-0.11	0.2	-0.12	-0.24	0.39	0.24	0.09	-0.1	-0.14	-0.2	-0.16	0.21
Accounts Payable	0.94	0.94	0.44	-0.06		0.92	0.94	-0.31	-0.38	0.56	0.96	0.22	0.77	0.96	0.58	0.75	-0.77	0.62	0.87	0.84	-0.77	0.9	0.91	0.86	-0.85
Total Liab	0.99	0.98	0.66	0.18	0.92		0.91	-0.48	-0.21	0.56	0.97	0.04	0.89	0.88	0.68	0.58	-0.85	0.85	0.94	0.89	-0.83	0.82	0.76	0.8	-0.71
Total Current Assets	0.95	0.96	0.3	0.04	0.94	0.91		-0.39	-0.16	0.71	0.9	0.34	0.78	0.92	0.58	0.79	-0.66	0.59	0.8	0.82	-0.7	0.85	0.89	0.79	-0.79
Common Stock	-0.48	-0.48	-0.44	-0.89	-0.31	-0.48	-0.39		-0.22	-0.37	-0.43	0.01	-0.5	-0.3	-0.42	-0.16	0.42	-0.54	-0.47	-0.42	0.35	-0.24	-0.2	-0.24	0.2
Short Term Debt	-0.18	-0.14	-0.21	0.4	-0.38	-0.21	-0.16	-0.22		0.14	-0.33	0.13	-0.17	-0.37	-0.19	-0.24	0.31	-0.07	-0.27	-0.22	0.61	-0.39	-0.47	-0.39	0.32
Current Deferred Revenue	0.61	0.64	0.06	0.08	0.56	0.56	0.71	-0.37	0.14		0.55	0.28	0.49	0.58	0.34	0.62	-0.11	0.31	0.29	0.5	-0.34	0.5	0.64	0.46	-0.72
Net Receivables	0.97	0.95	0.65	0.09	0.96	0.97	0.9	-0.43	-0.33	0.55		0.06	0.85	0.92	0.66	0.63	-0.84	0.78	0.93	0.89	-0.83	0.86	0.82	0.84	-0.8
Net Tangible Assets	0.09	0.15	-0.5	-0.18	0.22	0.04	0.34	0.01	0.13	0.28	0.06		0.14	0.28	0.03	0.22	0.12	-0.34	-0.06	0.16	0.13	0.28	0.35	0.28	-0.31
Long Term Debt	0.87	0.86	0.68	0.24	0.77	0.89	0.78	-0.5	-0.17	0.49	0.85	0.14		0.77	0.81	0.41	-0.75	0.84	0.82	0.95	-0.79	0.81	0.65	0.82	-0.57
Good Will	0.9	0.91	0.39	-0.11	0.96	0.88	0.92	-0.3	-0.37	0.58	0.92	0.28	0.77		0.54	0.7	-0.66	0.59	0.79	0.86	-0.71	0.95	0.93	0.94	-0.83
Long Term Debt Total	0.67	0.66	0.57	0.2	0.58	0.68	0.58	-0.42	-0.19	0.34	0.66	0.03	0.81	0.54		0.34	-0.64	0.68	0.67	0.74	-0.72	0.59	0.49	0.57	-0.38
Long Term Investments	0.65	0.68	-0.06	-0.12	0.75	0.58	0.79	-0.16	-0.24	0.62	0.63	0.22	0.41	0.7	0.34		-0.35	0.22	0.5	0.55	-0.44	0.71	0.82	0.56	-0.64
Treasury Stock	-0.81	-0.77	-0.78	-0.24	-0.77	-0.85	-0.66	0.42	0.31	-0.11	-0.84	0.12	-0.75	-0.66	-0.64	-0.35		-0.81	-0.96	-0.74	0.8	-0.62	-0.48	-0.61	0.49
Intangible Assets	0.81	0.77	0.9	0.39	0.62	0.85	0.59	-0.54	-0.07	0.31	0.78	-0.34	0.84	0.59	0.68	0.22	-0.81		0.85	0.79	-0.74	0.58	0.38	0.61	-0.37
Property Plant Equipment	0.92	0.9	0.72	0.24	0.87	0.94	0.8	-0.47	-0.27	0.29	0.93	-0.06	0.82	0.79	0.67	0.5	-0.96	0.85		0.82	-0.82	0.73	0.63	0.7	-0.56
Capital Surpluse	0.88	0.88	0.61	0.09	0.84	0.89	0.82	-0.42	-0.22	0.5	0.89	0.16	0.95	0.86	0.74	0.55	-0.74	0.79	0.82		-0.73	0.93	0.72	0.92	-0.67
Short Long Term Debt	-0.8	-0.76	-0.68	-0.1	-0.77	-0.83	-0.7	0.35	0.61	-0.34	-0.83	0.13	-0.79	-0.71	-0.72	-0.44	0.8	-0.74	-0.82	-0.73		-0.67	-0.68	-0.66	0.56
Net Invested Capital	0.83	0.84	0.38	-0.14	0.9	0.82	0.85	-0.24	-0.39	0.5	0.86	0.28	0.81	0.95	0.59	0.71	-0.62	0.58	0.73	0.93	-0.67		0.88	0.98	-0.75
Net Working Capital	0.8	0.82	0.16	-0.2	0.91	0.76	0.89	-0.2	-0.47	0.64	0.82	0.35	0.65	0.93	0.49	0.82	-0.48	0.38	0.63	0.72	-0.68	0.88		0.82	-0.81
Capital Stock	0.81	0.81	0.45	-0.16	0.86	0.8	0.79	-0.24	-0.39	0.46	0.84	0.28	0.82	0.94	0.57	0.56	-0.61	0.61	0.7	0.92	-0.66	0.98	0.82		-0.75
Accumulated Depreciation	-0.73	-0.73	-0.29	0.21	-0.85	-0.71	-0.79	0.2	0.32	-0.72	-0.8	-0.31	-0.57	-0.83	-0.38	-0.64	0.49	-0.37	-0.56	-0.67	0.56	-0.75	-0.81	-0.75

Click cells to compare fundamentals

Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.

Competition

Predict ANI Pharmaceuticals

Based on the latest financial disclosure, 11.1% of ANI Pharmaceuticals are shares owned by insiders. This is 26.88% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The shares owned by insiders for all United States stocks is 10.01% lower than that of the firm.

ANI Shares Owned By Insiders Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ANI Pharmaceuticals' direct or indirect competition against its Shares Owned By Insiders to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ANI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing ANI Pharmaceuticals by comparing valuation metrics of similar companies.

ANI Pharmaceuticals is currently under evaluation in shares owned by insiders category among its peers.

ANI Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ANI Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ANI Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

ANI Fundamentals

	Return On Equity	-0.016
	Return On Asset	0.0125
	Profit Margin	(0.01) %
	Operating Margin	(0.07) %
	Current Valuation	1.67 B
	Shares Outstanding	21.02 M
	Shares Owned By Insiders	11.10 %
	Shares Owned By Institutions	99.57 %
	Number Of Shares Shorted	2.16 M
	Price To Earning	43.35 X
	Price To Book	2.88 X
	Price To Sales	2.11 X
	Revenue	486.82 M
	Gross Profit	177.6 M
	EBITDA	109.32 M
	Net Income	18.78 M
	Cash And Equivalents	63.38 M
	Cash Per Share	3.89 X
	Total Debt	285.67 M
	Debt To Equity	0.85 %
	Current Ratio	3.35 X
	Book Value Per Share	20.74 X
	Cash Flow From Operations	118.96 M
	Short Ratio	11.73 X
	Earnings Per Share	(0.46) X
	Price To Earnings To Growth	1.06 X
	Target Price	78.4
	Number Of Employees	642
	Beta	0.71
	Market Capitalization	1.17 B
	Total Asset	904.42 M
	Retained Earnings	(80.13 M)
	Working Capital	374.34 M
	Current Asset	192.58 M
	Current Liabilities	11.76 M
	Net Asset	904.42 M

About ANI Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze ANI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ANI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ANI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with ANI Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against ANI Stock

0.54	DMAC	DiaMedica Therapeutics	Pair Corr
0.45	VRDN	Viridian Therapeutics	Pair Corr
0.36	SABSW	SAB Biotherapeutics	Pair Corr

The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.

The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ANI Stock Analysis

When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC